REGENXBIO Q2 net loss $72.1M ($1.66/sh); revenue $20M; RGX-121 enrollment complete

REGENXBIO Inc.

2023-Q2 EPS reported -$3.19 revenue$39,115,000

Net loss widened to $72.1M vs $68.2M YoY; diluted EPS -$1.66.
Revenue fell to $20.0M from $32.6M; Zolgensma royalty revenue down to $19.0M.
Cash, equivalents and marketable securities $415.4M; runway into 2025.
Completed enrollment (10 patients) in Phase III CAMPSIITE trial for RGX-121; BLA filing planned 2024.
ABBV-RGX-314 suprachoroidal dose level 3 with short-course steroids showed zero intraocular inflammation (N=39).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.